Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study

Author: Boér Katalin  

Publisher: Springer Publishing Company

ISSN: 0167-6997

Source: Investigational New Drugs, Vol.30, Iss.2, 2012-04, pp. : 681-687

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content